Error loading player: No playable sources found

Player size: small large

Rapid Selection, Characterization and Clinical Development of Fully‑Human Antibodies Against Emerging Infectious Diseases

Date

January 13, 2021

Speaker

Christos Kyratsous, PhD

Regeneron Pharmaceuticals Inc

Tracks

Antibodies as Drugs for COVID‑19

Related Products

Thumbnail for Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates

Highly Potent Anti‑SARS‑CoV‑2 Multivalent DARP in Therapeutic Candidates

Thumbnail for Coffee Break

Thumbnail for Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Combating COVID‑19: Identifying a Potential Drug Candidate for Human Testing in 90 Days

Thumbnail for When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19

When Size Matters: A Broadly Neutralizing Single Domain Antibody to Prevent and Treat COVID 19

Privacy Policy Update: We value your privacy and want you to understand how your information is being used. To make sure you have current and accurate information about this sites privacy practices please visit the privacy center by clicking here.